Replies to post #11816 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

Regarding footnote #2, it’s reassuring that MNTA has already addressed the “gene expression” question that Teva raised in a published article in 2013. I.e., gene expression is not a matter on which the FDA is likely to come back to MNTA with more questions.